医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Toyoda Gosei Invests in ThinkCyte, a Startup Developing Devices for the Early Detection of Leukemia and Other Diseases

2023年11月28日 PM03:00
このエントリーをはてなブックマークに追加


 

KIYOSU, Japan

Toyoda Gosei Co., Ltd. (TOKYO:7282) has invested* in ThinkCyte K.K., whose technologies are used for a broad spectrum of applications, including the early detection of leukemia and other diseases, with the aim of solving social issues in the healthcare field.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231127932516/en/

Cell sorter developed by ThinkCyte (Graphic: Business Wire)

Cell sorter developed by ThinkCyte (Graphic: Business Wire)

ThinkCyte is a startup developing and commercializing cell analysis and sorting technology platform using AI-based cell image analysis. The company’s technology to analyze individual cells and sort them will enable faster and more accurate diagnoses than conventional methods. Its technology also holds future promise for use in drug discovery.

Toyoda Gosei has been focusing efforts on product development and collaboration with companies in the field of preventive medicine, to help increase life expectancy. Using its technologies in the molding of plastic materials and mold processing, Toyoda Gosei will cultivate business in the healthcare field through its contributions to the commercialization of devices being developed by ThinkCyte.

* Investment made in October 2023, through Toyoda Gosei’s Corporate Venture Capital Dept., an internal organization dedicated to these investments.

Outline of ThinkCyte

Name

ThinkCyte K.K.

Location

7-3-1 Hongo, Bunkyo, Tokyo, Japan

CEO

Waichiro Katsuda

Established

February 2016

Capital

JPY 1.207 billion (as of August 2023)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20231127932516/en/

CONTACT

Toyoda Gosei Co., Ltd.

Contact: Public Relations

inquiry@mlist.toyoda-gosei.co.jp

同じカテゴリーの記事 

  • Celltrion在第19届ECCO大会上公布了皮下注射英夫利西单抗(CT-P13 SC)治疗炎症性肠病(IBD)的两年新数据
  • セルトリオン、第19回 ECCO会議で炎症性腸疾患(IBD)における皮下インフリキシマブ(CT-P13 SC)の2年間の新データを発表
  • Neuraptive Therapeutics, Inc. 公布了NTX-001在2期NEUROFUSE研究中表现积极的24周数据,强化了之前宣布的概念验证12周数据结果
  • ニューラプティブ・セラピューティクス、NTX-001に関する第2相NEUROFUSE研究における24週間の良好なデータを発表し、以前に発表した概念実証の12週間データを補強
  • 白内障手術用レンズの選択に、スイス製の新機能